Officials from the various municipalities have benefited from a workshop on sustainable management and development, held on Thursday at Cara Lodge in Quamina Street, Georgetown.Those present were addressed by Communities Minister Ronald Bulkan, who explained that participation is the key towards driving sustainability into the towns of Guyana.“In Guyana, we’re in a transition as far as the governance architecture is concerned. This is a transition from a centralised approach to governance to a decentralised one, and the trajectory is moving in a different direction,” the minister posited.He added that the restoration of these towns cannot be an ‘overnight endeavour,’ and would therefore involve work on the part of many entities and individuals.These discussions would also facilitate the ideas which would prove to be beneficial to the townships, after looking at external factors which would be assisted by the Office of the Climate Change of the Ministry of the Presidency.“Our local democratic organs, including our municipalities and NDCs (Neighbourhood Democratic Councils), are not cosmetic organs. They’re not appendages of the Central Government, but this shift from the centralised model that is largely obtained is not one that will happen overnight.”While highlighting the remodelling that was done to the newly introduced towns, Bulkan explained that Central Government is willing to extend a helping hand to see materialisation of the additional initiatives proposed by the councils.Bartica Mayor Gifford Marshall also shared his remarks on some of the initiatives that his town hopes to achieve in the future. These include the concepts of electric bicycles and hybrid cars, which they hope to bring soon to the community under collaborative efforts with public and private entities.In relation to Thursday’s planning and discussions, he advised, “Whenever we make decisions, our intentions are often in the right place but we have to able to analyse our decisions and consider the unintended consequences.”The mayors, town clerks and councillors of these respective towns, along with United Nations (UN) representatives, were given the chance to demonstrate their ideas and opinions for the establishment of sustainable townships.Meanwhile, from the discussions, it was revealed that some areas of concern should be taken into consideration before these are developed: such as acknowledgement of diversification, protecting and capitalising the natural resources, the inclusion of innovations and sustainable energy.
Excluding a benefit from foreign exchange rates, total product sales rose 13 percent and international product sales rose 15 percent, the company said. Strong demand helped drive worldwide sales of the anemia-fighting drug Aranesp to $1.02 billion, up 14 percent compared to $893 million during the first quarter of 2006. Sales of Epogen, which is also used to treat anemia in chemotherapy patients, rose 3 percent to $625 million, compared to $604 million in the year-ago quarter. Combined sales of Neulasta and Neupogen, which prevent infections in chemotherapy patients, rose 14 percent to $1.02 billion, compared to $896 million in the year-ago period. The growth was driven primarily by rising demand for Neulasta, Amgen said. North American sales of Amgen’s rheumatoid arthritis drug, Enbrel, rose 11 percent to $730 million, compared to $658 million a year ago. Last week, the company disclosed the results of an Aranesp study that showed there wasn’t a statistically significant difference in the risk of death when compared to placebo, meaning the drug failed to help late-stage cancer patients receiving chemotherapy live longer. The drug, which works by raising a person’s red blood cell count, was approved to treat anemia associated with chronic kidney failure. It was the company’s best-selling drug last year, with $4.12 billion in sales. Patients in the clinical trial who received the drug showed a significant boost in hemoglobin concentration and a significantly lower risk of blood transfusion, compared to placebo. Shares of Amgen rose 22 cents to close at $62.19 on the Nasdaq Stock Market. 160Want local news?Sign up for the Localist and stay informed Something went wrong. Please try again.subscribeCongratulations! You’re all set! THOUSAND OAKS – Amgen Inc., the world’s most profitable biotechnology company, reported higher first-quarter profit and revenue Monday on strong sales of its anemia-fighting drugs, but its revenue total for the quarter failed to meet Wall Street’s expectations. For the quarter ended March 31, the Thousand Oaks company reported net income of $1.11 billion, or 94 cents a share, compared with $1 billion, or 82 cents per share, in the year-ago quarter. Adjusted for expenses related to employee stock-options, costs associated with company acquisitions and other expenses, the company said it earned $1.27 billion, or $1.08 a share. On that basis, the earnings met Wall Street analysts’ expectations for earnings per share, according to a survey by Thomson Financial. Amgen’s total revenue rose 15 percent to $3.68 billion, from $3.21 billion in the same quarter last year. Analysts surveyed by Thomson Financial had expected sales of $3.73 billion. Amgen said it expects its adjusted earnings per share for the year to be on the low end of $4.30 and $4.50 per share. The company said it was reviewing its guidance for future revenue and would seek to cut operating expenses. “Our key products delivered good sales growth during the quarter,” Kevin Sharer, Amgen’s chairman and chief executive, said in a statement. Total product sales rose 14 percent during the most recent quarter to $3.6 billion, compared to $3.1 billion in the year-ago period. Amgen’s U.S. sales totaled $2.9 billion, up 12 percent from $2.6 billion in the same period last year. International sales rose 22 percent to $681 million from $556 million in the year-ago period.